| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Research Abstract |
Pediatric SMARCB1/INI1 (INI1)-deficient tumors were able to be re-classified into the three groups: conventional type, atypical teratoid/rhabdoid (AT/R) type and small cell type. Activation in Akt-mTOR pathway was found more frequently in AT/R and small cell types than in conventional type. Meanwhile, in most cases of epithelioid sarcoma (ES) including both conventional and proximal types, the Akt-mTOR pathway was activated.
It is suggested that mTOR inhibition is a potential treatment option for AT/R and small cell types of pediatric INI1-deficient tumor and ES. ES and malignant rhabdoid tumor are suggested to be distinct tumor entities.
|
